The U.S. Clinical Trials Landscape Is Changing. Which Opportunities Should Pharma Leaders Watch?

The United States remains one of the world's most important destinations for clinical research. Pharmaceutical companies, biotechnology developers and medical device manufacturers rely on U.S. research sites, academic medical centres and specialized clinical research organizations to evaluate new treatments.

However, trial performance depends on more than the number of research facilities. Patient recruitment, site activation, regulatory coordination, data quality and participant diversity all influence development timelines and costs.

The next phase of clinical research is likely to place greater emphasis on faster trial execution, connected data systems and more efficient collaboration between sponsors, research sites and regulators.

Download Customized/Ready to Use Sample PDF: https://www.towardshealthcare.com/download-sample/6455 

U.S. Clinical Trials: Industry Snapshot

The United States has a substantial clinical research base.

• 208,615 clinical trial registrations: WHO data recorded this U.S. total between 1999 and June 2026, making it the highest country total in the cited dataset.

• 8.2 million U.S.-site participants: NIH-supported clinical research enrolled 8,202,424 participants at U.S. sites during FY2025. Worldwide enrollment across the NIH-supported portfolio was approximately 11 million.

The NIH figure covers participants enrolled in NIH-supported clinical research, not the entire U.S. clinical trial industry. It demonstrates the scale of the research infrastructure but should not be interpreted as the number of unique patients participating across all U.S. trials.

Key Segments of the U.S. Clinical Trials Ecosystem

1. Phase I–IV Drug and Biologic Trials

Clinical development spans early safety and dose evaluation through large-scale efficacy and post-marketing studies.

• Phase I: Initial safety, tolerability and dose evaluation.

• Phase II: Early assessment of efficacy and further safety evaluation.

• Phase III: Larger studies to confirm efficacy and monitor safety.

• Phase IV: Post-marketing studies and additional evidence generation.

Biotechnology companies developing oncology, immunology, rare disease and advanced therapies continue to require specialized trial capabilities across these stages.

2. Oncology, Rare Disease and Cell and Gene Therapy Trials

Specialized therapeutic areas create distinct operational requirements.

Oncology trials may require biomarker testing, molecular profiling and complex patient eligibility assessments. Rare disease studies often face limited patient populations and geographically dispersed participants.

Cell and gene therapy trials require additional coordination around patient identification, manufacturing slots, treatment scheduling, chain of identity and specialized clinical-site capabilities.

These requirements create opportunities for specialized CROs, research hospitals, laboratory providers and technology companies.

3. Medical Device and Diagnostic Trials

Medical device studies require clinical evidence to support safety, performance and regulatory submissions.

The research process may involve investigator training, device accountability, imaging assessments, procedural documentation and long-term follow-up.

Diagnostic companies also need clinical studies to establish analytical and clinical performance for new testing technologies.

4. Decentralized and Hybrid Clinical Trials

Decentralized clinical trials use digital technologies and remote processes to support participation outside traditional research facilities.

Common capabilities include:

• Remote patient monitoring.

• Electronic informed consent.

• Telehealth consultations.

• Digital patient-reported outcomes.

• Home-based sample collection.

• Direct-to-patient investigational product logistics.

Hybrid models combine conventional research-site visits with remote activities. They can improve access for selected participants, although the appropriate model depends on the study design, investigational product and regulatory requirements.

Regulatory Developments Changing U.S. Clinical Research

FDA: Real-Time Clinical Trials Initiative

On April 28, 2026, the U.S. Food and Drug Administration announced steps to advance Real-Time Clinical Trials (RTCT).

The agency reported the initiation of two proof-of-concept trials designed to provide clinical endpoints and data signals in real time. It also released a Request for Information on a proposed pilot programme.

The initiative aims to give regulators earlier access to relevant trial information rather than relying exclusively on conventional reporting timelines. This could support faster review of emerging safety and efficacy signals while maintaining appropriate oversight. <Cite refs={["turn305546search2"]}/>

For technology providers, this creates opportunities in data integration, analytics, monitoring infrastructure and secure information exchange.

HHS: Operation TrialBlazer

On June 22, 2026, the Department of Health and Human Services launched Operation TrialBlazer, a department-wide effort to strengthen U.S. clinical research capacity.

The initiative focuses on reducing development delays, modernizing regulatory processes, expanding innovative research tools and making the United States a more attractive location for clinical development.

For pharmaceutical sponsors and CROs, these developments make domestic trial infrastructure, regulatory support and research-site partnerships important areas to monitor.

NIH and NCI: Participant Representation and Recruitment

NIH continues to publish enrollment data covering participant sex, race, ethnicity and age. Its FY2025 data provide a detailed view of participation across NIH-supported research.

For sponsors, representation is not simply a recruitment target. Appropriate participant diversity can help determine whether clinical evidence is relevant to the populations expected to use a treatment.

NCI-supported research also provides an important infrastructure for oncology trials through its clinical research networks and participating cancer centres.

Companies and Organizations Shaping the Clinical Trials Ecosystem

The U.S. clinical research ecosystem includes regulators, research institutions, CROs, site networks and technology providers.

The competitive position of these organizations depends on therapeutic expertise, geographic coverage, site relationships, recruitment performance, technology capabilities and sponsor experience.

Where Are the Biggest Market Gaps?

1. Slow Patient Recruitment and Site Activation

Identifying eligible participants and activating research sites can delay study initiation. Complex eligibility criteria, fragmented patient records and limited site capacity can make recruitment difficult.

2. Uneven Participant Representation

Some populations remain underrepresented in clinical research. Geographic barriers, access to research centres, language requirements and limited awareness can affect enrollment.

3. Fragmented Trial Data and Operations

Sponsors often coordinate data across research sites, laboratories, electronic data capture platforms, imaging providers and external vendors. Disconnected systems can increase reconciliation work and slow decision-making.

4. Complex Regulatory and Documentation Requirements

Clinical trials involve extensive documentation, safety reporting, protocol compliance and data-quality controls. Sponsors and sites need systems that support accurate records and timely reporting.

5. Limited Access to Specialized Research Sites

Not every research site has the infrastructure, investigators or patient population required for advanced oncology, rare disease and cell and gene therapy trials.

Business Opportunities for Pharmaceutical and Technology Companies

1. AI-Enabled Patient Matching and Recruitment

AI-based tools can help identify potentially eligible participants using structured clinical data, study criteria and approved recruitment workflows.

Opportunity: Develop patient-matching platforms, recruitment analytics and referral tools that integrate with research-site systems while maintaining privacy and appropriate human oversight.

2. Decentralized Trial Infrastructure

Remote monitoring, electronic consent, telehealth and digital patient-reported outcomes can support selected trial activities outside traditional sites.

Opportunity: Build integrated decentralized trial platforms and partnerships with healthcare providers, home-care services and digital health companies.

3. Specialized CRO and Research-Site Networks

Sponsors need access to sites with experience in specific therapeutic areas, patient populations and trial designs.

Opportunity: Identify underserved therapeutic segments and develop specialized site networks, investigator partnerships and CRO service capabilities.

4. Real-Time Data Platforms and Clinical Analytics

The FDA's real-time trial initiative highlights the importance of timely access to reliable clinical data.

Opportunity: Develop data integration, analytics, safety monitoring and reporting platforms that support sponsors, research sites and regulators.

5. Clinical Trial Diversity and Patient Access Solutions

Improving participant representation requires more than digital advertising. It involves accessible research locations, community partnerships, patient education and practical support.

Opportunity: Develop recruitment networks and patient-access programmes that help sponsors engage populations historically underrepresented in clinical studies.

What Should Pharma Leaders and Investors Track?

These indicators can help identify which therapeutic areas are attracting research activity, where trial capacity is developing and which service providers may benefit from increased sponsor demand.

How Towards Healthcare Supports Clinical Trials Intelligence

Towards Healthcare Research & Consulting supports pharmaceutical companies, biotechnology developers, CROs, research organizations and investors through structured clinical research intelligence.

Relevant services include:

• Complete Master Datasets: Clinical trial sponsors, drug candidates, therapeutic areas, trial phases, research sites and development activity.

• Competitive Quadrants: Benchmarking CROs, clinical research providers and technology companies based on capabilities, geographic presence and specialization.

• Customized Dashboards: Tracking trial registrations, clinical milestones, sponsor activity, site networks and partnerships.

• Pipeline Intelligence: Monitoring investigational products, trial progress, development changes and regulatory milestones.

• Buyer Identification: Identifying pharmaceutical sponsors, biotech companies, research institutions, CROs and potential technology buyers.

• GTM Strategy: Assessing therapeutic segments, geographic opportunities, research partnerships and service-provider positioning.

The Strategic Outlook

The U.S. clinical trials landscape is evolving through regulatory modernization, digital research infrastructure and growing attention to patient access and representation.

The next competitive advantage will depend on how effectively sponsors connect patients, research sites, technology providers and regulatory processes.

For pharmaceutical leaders, CROs and investors, the opportunity is to identify where trial execution remains inefficient and which organizations are building the capabilities to address those gaps.

Explore U.S. clinical trial sponsors, research sites, CROs and emerging partnership opportunities with Towards Healthcare.

About Us

Healthcare WebWire is a part of Towards Healthcare, which is a healthcare intelligence and market research company specializing in market intelligence, competitive intelligence, customer intelligence, pipeline intelligence, market sizing and commercial strategy across pharmaceutical, biotechnology, medical device and healthcare markets.

Contact us for quick meeting, customized data, free samples or further enquiry at [email protected]

Europe Region - +44 778 256 0738

North America Region - +1 8044 4193 44

APAC Region: +91 9356 9282 04

Visit Our Website: https://www.towardshealthcare.com

                 Find us on social platforms: LinkedIn | Twitter | Instagram